Wednesday, November 11, 2026

Uber Exits In-House Autonomous Development, Banks on Wayve and Rivian Partnerships

Uber sold its autonomous vehicle unit in December 2020 and shifted to partnerships with specialized AV companies including Wayve, Chinese firms, and Rivian. The strategy replaces capital-intensive internal R&D with investments in external AV developers. Uber has taken equity positions in both Wayve and Rivian to secure access to their autonomous technology.

LM Salvado

March 25, 2026

Uber Exits In-House Autonomous Development, Banks on Wayve and Rivian Partnerships
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.
Loading stream...

Uber sold its Uber ATG autonomous vehicle unit in December 2020, ending years of internal development. The company has since replaced proprietary tech efforts with a partnership model centered on specialized autonomous vehicle firms.

The rideshare giant announced partnerships with UK-based Wayve and multiple Chinese AV companies. Uber also struck a robotaxi deal with electric vehicle maker Rivian, with negotiations reportedly spanning an extended period.

Uber backed the strategy with capital commitments. The company invested in both Wayve and Rivian Automotive, taking equity stakes in the AV developers. This approach gives Uber technology access without maintaining large internal engineering teams.

The pivot reflects a broader industry split between vertically integrated players like Tesla and Waymo, who develop full-stack autonomous systems, versus platform operators who aggregate third-party technology. Uber's model resembles its core rideshare business: own the marketplace, not the underlying assets.

Partnership economics differ sharply from in-house development. Internal AV programs require sustained R&D spending on sensors, compute hardware, simulation infrastructure, and safety validation. Uber ATG burned through capital without reaching commercial deployment before its sale.

The external model shifts timing risk to partners. Wayve and Rivian absorb development costs and deployment delays. Uber gains optionality across multiple technology approaches rather than betting on a single internal architecture.

Execution depends on partner delivery timelines and integration complexity. Uber must adapt its platform to support different autonomous systems from Wayve, Chinese providers, and Rivian. Coordinating safety standards, liability frameworks, and operational protocols across vendors adds overhead.

The strategy also creates dependency. If key partners stumble or prioritize competing platforms, Uber loses control over its autonomous roadmap. Equity investments provide some alignment but not operational authority.

Competition remains intense. Waymo operates commercial robotaxi services in multiple cities. Cruise has resumed testing after regulatory setbacks. Tesla's Full Self-Driving software reaches millions of vehicles. Uber's partnership approach must deliver comparable service quality and unit economics to compete.

In this story

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,564 source documents archived
Query this data → isubstrate.com